ENZON PHARMACEUTICALS INC
ENZN
ENZN was delisted on the 19th of May, 2016.
53 hedge funds and large institutions have $18.4M invested in ENZON PHARMACEUTICALS INC in 2015 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 15 increasing their positions, 13 reducing their positions, and 11 closing their positions.
1,200% more call options, than puts
Call options by funds: $13K | Put options by funds: $1K
15% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 13
9% less funds holding
Funds holding: 58 → 53 (-5)
22% less capital invested
Capital invested by funds: $23.7M → $18.4M (-$5.29M)
45% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$235K |
| 2 |
GC
Globeflex Capital
San Diego,
California
|
+$186K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$138K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$118K |
| 5 |
KBC Group
Brussels,
Belgium
|
+$108K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Ativo Capital Management
Chicago,
Illinois
|
-$575K |
| 2 |
SIM
Spark Investment Management
New York
|
-$338K |
| 3 |
BIP
Brandes Investment Partners
La Jolla,
California
|
-$310K |
| 4 |
AL
Airain Ltd
St. Peter Port,
Guernsey
|
-$132K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
-$128K |
ENZN Hedge Fund Activity: Q3 2015 in Review
53 of the 3,583 institutional investors tracked by Wall St. Rank reported a position in ENZON PHARMACEUTICALS INC (ENZN) for Q3 2015, worth a combined $18.4M — down 22% from $23.7M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of ENZN and 6 opened new positions — a net loss of 5 holders — while 13 trimmed existing stakes and 15 added.
The largest buyer was Connor, Clark & Lunn Investment Management (CC&L), adding an estimated $235K. The largest seller was Ativo Capital Management, exiting entirely with an estimated $575K sold.
- 53 institutional investors held ENZON PHARMACEUTICALS INC (ENZN) as of Q3 2015, down from 58 in Q2 2015.
- Funds reported $18.4M of ENZON PHARMACEUTICALS INC stock for Q3 2015, down 22% quarter-over-quarter.
- 6 funds opened new ENZON PHARMACEUTICALS INC positions in Q3 2015 and 11 closed out, a net change of -5 holders.
- The largest ENZON PHARMACEUTICALS INC buyer in Q3 2015 was Connor, Clark & Lunn Investment Management (CC&L), an estimated $235K added.
- The largest ENZON PHARMACEUTICALS INC seller in Q3 2015 was Ativo Capital Management, an estimated $575K sold.
Based on aggregated 13F filings for Q3 2015.